These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 28188299)

  • 1. Novel Mechanism of Decyanation of GDC-0425 by Cytochrome P450.
    Takahashi RH; Halladay JS; Siu M; Chen Y; Hop CE; Khojasteh SC; Ma S
    Drug Metab Dispos; 2017 May; 45(5):430-440. PubMed ID: 28188299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical assessment of the absorption, distribution, metabolism and excretion of GDC-0449 (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide), an orally bioavailable systemic Hedgehog signalling pathway inhibitor.
    Wong H; Chen JZ; Chou B; Halladay JS; Kenny JR; La H; Marsters JC; Plise E; Rudewicz PJ; Robarge K; Shin Y; Wong S; Zhang C; Khojasteh SC
    Xenobiotica; 2009 Nov; 39(11):850-61. PubMed ID: 19845436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of metabolism and disposition of GDC-0152 in rats using 14C labeling strategy at two different positions: a novel formation of hippuric acid from 4-phenyl-5-amino-1,2,3-thiadiazole.
    Yue Q; Mulder T; Rudewicz PJ; Solon E; Budha N; Ware JA; Lyssikatos J; Hop CE; Wong H; Khojasteh SC
    Drug Metab Dispos; 2013 Feb; 41(2):508-17. PubMed ID: 23223496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human.
    Salphati L; Pang J; Plise EG; Lee LB; Olivero AG; Prior WW; Sampath D; Wong S; Zhang X
    Drug Metab Dispos; 2012 Sep; 40(9):1785-96. PubMed ID: 22696419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A supported liquid extraction LC-MS/MS method for determination of concentrations of GDC-0425, a small molecule Checkpoint kinase 1 inhibitor, in human plasma.
    Ding X; Chen Y; Sahasranaman S; Shi Y; McKnight J; Dean B
    Biomed Chromatogr; 2016 Dec; 30(12):1984-1991. PubMed ID: 27245274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in Humans.
    Takahashi RH; Choo EF; Ma S; Wong S; Halladay J; Deng Y; Rooney I; Gates M; Hop CE; Khojasteh SC; Dresser MJ; Musib L
    Drug Metab Dispos; 2016 Jan; 44(1):28-39. PubMed ID: 26451002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical disposition of GDC-0973 and prospective and retrospective analysis of human dose and efficacy predictions.
    Choo EF; Belvin M; Boggs J; Deng Y; Hoeflich KP; Ly J; Merchant M; Orr C; Plise E; Robarge K; Martini JF; Kassees R; Aoyama RG; Ramaiya A; Johnston SH
    Drug Metab Dispos; 2012 May; 40(5):919-27. PubMed ID: 22315332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absorption, distribution, metabolism, and excretion of [¹⁴C]GDC-0449 (vismodegib), an orally active hedgehog pathway inhibitor, in rats and dogs: a unique metabolic pathway via pyridine ring opening.
    Yue Q; Chen YH; Mulder T; Deese A; Takahashi R; Rudewicz PJ; Reynolds M; Solon E; Hop CE; Wong H; Khojasteh SC
    Drug Metab Dispos; 2011 Jun; 39(6):952-65. PubMed ID: 21363998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro metabolism of tirilazad mesylate in male and female rats. Contribution of cytochrome P4502C11 and delta 4-5 alpha-reductase.
    Wienkers LC; Steenwyk RC; Mizsak SA; Pearson PG
    Drug Metab Dispos; 1995 Mar; 23(3):383-92. PubMed ID: 7628305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolism of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737): identification of an unusual N-acetylglucosamine conjugate in the cynomolgus monkey.
    Johnson BM; Kamath AV; Leet JE; Liu X; Bhide RS; Tejwani RW; Zhang Y; Qian L; Wei DD; Lombardo LJ; Shu YZ
    Drug Metab Dispos; 2008 Dec; 36(12):2475-83. PubMed ID: 18787055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolism and disposition of [14C]BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor, after oral administration to humans.
    Christopher LJ; Hong H; Vakkalagadda BJ; Clemens PL; Su H; Roongta V; Allentoff A; Sun H; Heller K; Harbison CT; Iyer RA; Humphreys WG; Wong T; Zhang S
    Drug Metab Dispos; 2010 Nov; 38(11):2049-59. PubMed ID: 20668249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N,N',N''-triethylenethiophosphoramide (thio-TEPA) oxygenation by constitutive hepatic P450 enzymes and modulation of drug metabolism and clearance in vivo by P450-inducing agents.
    Ng SF; Waxman DJ
    Cancer Res; 1991 May; 51(9):2340-5. PubMed ID: 1707751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elucidating the Mechanisms of Formation for Two Unusual Cytochrome P450-Mediated Fused Ring Metabolites of GDC-0623, a MAPK/ERK Kinase Inhibitor.
    Takahashi RH; Ma S; Robinson SJ; Yue Q; Choo EF; Khojasteh SC
    Drug Metab Dispos; 2015 Dec; 43(12):1929-33. PubMed ID: 26438627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP1A1-Mediated Intramolecular Rearrangement of Aminoazepane in GDC-0339.
    Takahashi RH; Wang X; Segraves NL; Wang J; Chang JH; Khojasteh SC; Ma S
    Drug Metab Dispos; 2017 Oct; 45(10):1084-1092. PubMed ID: 28790146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans.
    Dowty ME; Lin J; Ryder TF; Wang W; Walker GS; Vaz A; Chan GL; Krishnaswami S; Prakash C
    Drug Metab Dispos; 2014 Apr; 42(4):759-73. PubMed ID: 24464803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elucidating the structure and cytochrome P450-mediated mechanism for novel metabolites of GDC-0575 in rats.
    Zhang C; Cho S; Napolitano JG; Russell D; Gu C; Deese A; Han C; Chen Y; Ma S
    Xenobiotica; 2022 Mar; 52(3):219-228. PubMed ID: 35379057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.
    Beland FA
    Toxic Rep Ser; 1999 Aug; (59):1-66, A1-E7. PubMed ID: 11803702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiolabel Uncovers Nonintuitive Metabolites of BIIB104: Novel Release of [
    Gu C; Huang J; Muste C; Zhong J; Walker GS; Obach RS; Shaffer CL
    Drug Metab Dispos; 2024 Apr; 52(5):323-336. PubMed ID: 38360917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolism and Disposition of a Novel B-Cell Lymphoma-2 Inhibitor Venetoclax in Humans and Characterization of Its Unusual Metabolites.
    Liu H; Michmerhuizen MJ; Lao Y; Wan K; Salem AH; Sawicki J; Serby M; Vaidyanathan S; Wong SL; Agarwal S; Dunbar M; Sydor J; de Morais SM; Lee AJ
    Drug Metab Dispos; 2017 Mar; 45(3):294-305. PubMed ID: 27993930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.